Skip to main content

Xenon Pharmaceuticals Inc.

XENE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001582313

In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; Duquesne Family Office is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Xenon Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $1.07M in total
Insiders trading
2
Net value
−$1.07M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Xenon Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Xenon Pharmaceuticals Inc.
NameTitleLast reported holdingLast filingFilings, past year
Svoronos DawnDirector31,373Sep 3, 20262
Kenney Christopher JohnChief Medical Officer2Aug 31, 20264
Gannon StevenDirector1,870Aug 13, 20263
Patou GaryDirector24,896Jun 8, 20262
Cannon GillianDirector1,455Jun 8, 20262
Machado PatrickDirector2,645Jun 3, 20261
Gover Justin D.Director2,645Jun 3, 20261
Garofalo Elizabeth A.Director2,645Jun 3, 20261
Mortimer IanPRESIDENT & CEO19,923Mar 13, 20267
DiFabio AndreaChief Legal Officer7,301Mar 13, 20263
Cline Darren SChief Commercial Officer–Jan 9, 20261
Kelly Thomas PatrickChief Financial Officer–Oct 17, 20251
Aulin SherryChief Financial Officer0Dec 19, 20240
Robin SherringtonEVP, Strategy & Innovation8,398Mar 12, 20240
Empfield James R.EVP, Drug Discovery10,000Mar 12, 20240
Von Seggern ChristopherChief Commercial Officer4,000Mar 12, 20240
Azab MohammadDirector74,225Dec 20, 20230
Pimstone Simon N.Director6,000Jun 2, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 31, 2026 (view filing)9:59 PM ETAug 283 daysKenney Christopher JohnChief Medical OfficerSSale−7.07K$60.25−$425.8K−100.0%2 after2 lots10b5-1
Aug 13, 2026 (view filing)4:33 PM ETAug 112 daysGannon StevenDirectorSSale−10.0K$64.06−$640.5K−84.2%1.87K after
Jun 8, 2026 (view filing)Jun 53 daysPatou GaryDirectorSSale−1.32K$53.14−$70.3K−5.0%24.9K after10b5-1
Jun 8, 2026 (view filing)Jun 53 daysCannon GillianDirectorSSale−1.19K$53.14−$63.2K−45.0%1.46K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayKenney Christopher JohnChief Medical OfficerSSale−1.41K$55.23−$77.9K−16.6%7.07K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayDiFabio AndreaChief Legal OfficerSSale−1.34K$55.23−$74.1K−15.5%7.30K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayMortimer IanPRESIDENT & CEOSSale−7.31K$55.23−$403.6K−26.8%19.9K after10b5-1
Mar 11, 2026 (view filing)Mar 101 dayKenney Christopher JohnChief Medical OfficerSSale−2.77K$60.11−$166.6K−36.9%4.73K after10b5-1
Mar 11, 2026 (view filing)Mar 101 dayDiFabio AndreaChief Legal OfficerSSale−2.61K$60.11−$156.7K−34.8%4.89K after10b5-1
Mar 11, 2026 (view filing)Mar 9-102 daysMortimer IanPRESIDENT & CEOSSale−281.3K$60.32−$17.0M−95.0%14.7K after10 lots10b5-1
Jan 2, 2026 (view filing)Jan 2Same dayMortimer IanPRESIDENT & CEOSSale−40.0K$44.43−$1.78M−87.0%6.00K after2 lots10b5-1
Dec 9, 2025 (view filing)Dec 5-84 daysMortimer IanPRESIDENT & CEOSSale−25.2K$45.33−$1.14M−80.8%6.00K after3 lots10b5-1
Dec 3, 2025 (view filing)Nov 285 daysLateMortimer IanPRESIDENT & CEOSSale−97$45.01−$4.37K−0.3%31.2K after10b5-1
Oct 1, 2025 (view filing)Oct 1Same dayMortimer IanPRESIDENT, CEO & INTERIM CFOSSale−25.0K$40.16−$1.00M−44.4%31.3K after10b5-1
Jun 6, 2025 (view filing)Jun 51 dayGannon StevenDirectorSSale−3$30.48−$91.440.0%7.14K after
Jan 27, 2025 (view filing)Jan 23-274 daysMortimer IanPRESIDENT & CEOSSale−55.0K$40.25−$2.21M−63.7%31.3K after4 lots10b5-1
Dec 19, 2024 (view filing)Dec 181 dayAulin SherryChief Financial OfficerSSale−18.7K$41.21−$770.9K−100.0%0 after2 lots
Nov 22, 2024 (view filing)Nov 22Same dayPatou GaryDirectorSSale−4.89K$41.08−$200.9K−17.2%23.6K after2 lots
Mar 11, 2024 (view filing)Mar 83 daysGarofalo Elizabeth A.DirectorSSale−2.09K$45.69−$95.6K−100.0%0 after
Mar 8, 2024 (view filing)Mar 71 dayRobin SherringtonEVP, Strategy & InnovationSSale−7.14K$46.28−$330.3K−45.9%8.40K after2 lots
Mar 8, 2024 (view filing)Mar 71 dayGannon StevenDirectorSSale−13.0K$46.28−$601.6K−86.7%2.00K after4 lots
Dec 15, 2023 (view filing)Dec 141 dayPatou GaryDirectorSSale−7.60K$41.05−$311.9K−60.8%4.90K afterAmended
Aug 24, 2023 (view filing)Aug 24Same daySvoronos DawnDirectorSSale−25.0K$38.70−$967.5K−50.0%25.0K after
Jun 1, 2023 (view filing)May 30-Jun 12 daysPimstone Simon N.DirectorSSale−131.2K$38.90−$5.10M−95.6%6.00K after7 lots
May 26, 2023 (view filing)May 242 daysMortimer IanPRESIDENT & CEOSSale−31.7K$41.41−$1.31M−50.3%31.3K after3 lots
Mar 24, 2023 (view filing)Mar 24Same dayKenney Christopher JohnChief Medical OfficerSSale−700$35.01−$24.5K−100.0%0 after
Mar 9, 2023 (view filing)Mar 72 daysPimstone Simon N.DirectorSSale−19.2K$36.98−$711.2K−25.9%55.0K after2 lots
Nov 28, 2022 (view filing)Nov 23-255 daysPatou GaryDirectorSSale−3.99K$34.55−$138.0K−14.5%23.6K after2 lots
Sep 7, 2022 (view filing)Sep 25 daysAulin SherryChief Financial OfficerSSale−15.4K$39.57−$607.6K−100.0%0 after
Sep 2, 2022 (view filing)Aug 31-Sep 12 daysRobin SherringtonEVP, Strategy & InnovationSSale−65.2K$38.31−$2.50M−79.5%16.8K after3 lots
Aug 16, 2022 (view filing)Aug 124 daysEmpfield James R.EVP, Drug DiscoverySSale−57.7K$38.31−$2.21M−85.2%10.0K after2 lots
Aug 16, 2022 (view filing)Aug 12-164 daysPimstone Simon N.DirectorSSale−177.1K$38.25−$6.78M−96.7%6.00K after6 lots
Mar 8, 2022 (view filing)Mar 8Same dayPimstone Simon N.DirectorSSale−2.50K$30.80−$77.0K−1.3%193.1K afterAmended
Mar 8, 2022 (view filing)Mar 44 daysRobin SherringtonEVP, Strategy & InnovationSSale−21.7K$30.50−$662.2K−55.7%17.2K after4 lots
Mar 8, 2022 (view filing)Mar 4-74 daysEmpfield James R.EVP, Drug DiscoverySSale−51.2K$30.63−$1.57M−83.7%10.0K after3 lots
Jan 21, 2022 (view filing)Jan 21Same dayKenney Christopher JohnChief Medical OfficerPPurchase+700$28.81+$20.2KNew position700 after
Dec 7, 2021 (view filing)Dec 61 dayVon Seggern ChristopherChief Commercial OfficerPPurchase+4.00K$24.40+$97.6KNew position4.00K after
Nov 16, 2021 (view filing)Nov 151 dayPimstone Simon N.DirectorSSale−17.6K$31.33−$550.1K−7.7%210.2K after